Seventh Sense's technology brings together recent advances in the fields of nanosensors, biopolymers, and skin interface devices to create a powerful platform for next-generation diagnostics. Our company is at the forefront of applying significant advances in these fields developed at MIT, Massachusetts General Hospital, University of Michigan, and UC Santa Barbara to produce a novel class of products that will have widespread impact in multiple healthcare settings.
Seventh Sense's particle platform is based on switchable materials developed in the laboratories of our Company's academic co-founders. Biphasic particles are a type of switchable material that contains two distinct hemispheric phases, each of which can be loaded with different materials, such as dyes, and can be independently surface-functionalized. By functionalizing biphasic particles loaded with two different dyes with capture ligands that specifically bind analytes of interest, bioresponsive particles can be engineered.
When the particles bind to a surface or to other particles, they self-orient in a way that displays a visible color change. This type of response is the foundation of Seventh Sense's simple biosensor devices.
Particle properties, including size, shape, surface charge, multiphasic compartmentalization, and functionalization, can be precisely controlled to achieve desired particle characteristics. By coupling the particles to biological analyte sources, it is possible to create novel diagnostics that can register the presence of specific analytes, either small or large molecules, involved in health and disease states.